№ files_lp_4_process_2_55251
File format: docx
Character count: 5254
File size: 40 KB
Structured form for tracking the progress, personnel, and sample usage of ALS research projects linked to the National ALS Registry or biorepository.
Year:
201x
Document Type:
Annual Update Form
Issuing Organization:
ATSDR / CDC
Target Audience:
Principal Investigators and Co-Investigators
Project Number:
As indicated in form
Study Title:
As indicated in form
IRB Requirement:
If applicable, continuation approval required
Sample Types:
Blood, Plasma, Serum, Urine, RNA, DNA, Hair, Nails, Brain, Spinal cord, Cerebral spinal fluid, Muscle, Primary dermal fibroblasts, Bone
Research Technologies:
RNA isolation, DNA isolation, Protein isolation, Laser microdissection, Immunohistochemistry, RT/PCR, RNA amplification, Microarray, PCR, FISH/CGH, Proteomics, Gene mapping/SNP analysis, Mutation analysis/sequencing, Enzymology, Immunoblot/immunoprecipitation, Pharmacogenomics, Pharmacokinetics, Serology/antibody studies, Biomarker analysis
Update Frequency:
Annual, on anniversary of project approval
Project Status Options:
Not yet begun, In progress, Completed, Suspended or Terminated
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
2023
Region / City:
Buffalo, New York
Topic:
Biorepository, Biobanking, Quality Standards
Document Type:
Policy Manual
Organization:
University at Buffalo
Author:
Not specified
Target Audience:
Researchers, Industry Partners, Biorepository Staff
Period of Validity:
Not specified
Date of Approval:
Not specified
Date of Changes:
Not specified
Year:
2023
Region / City:
United States
Topic:
Biorepository, Laboratory Research, Strain Catalog
Document Type:
FAQ
Organization:
ARLG Laboratory Center
Author:
ARLG Laboratory Center
Target Audience:
Researchers, Investigators
Period of Validity:
Ongoing
Approval Date:
Not specified
Date of Changes:
Not specified
Year:
2023
Region / City:
United States
Topic:
Virtual Biorepository, Laboratory Resources
Document Type:
FAQ
Organization:
ARLG Laboratory Center
Author:
ARLG Laboratory Center Team
Target Audience:
Researchers, Investigators
Effective Period:
Ongoing
Approval Date:
Not specified
Date of Changes:
Not specified
Note:
Year
Survey Data Available:
Yes / No
Year:
2020
Region / city:
Not specified
Topic:
Safety and reliability in power export curtailment
Document type:
Workshop topics and discussion points
Organization:
Not specified
Author:
Not specified
Target audience:
Utility companies, grid operators, energy regulators
Period of validity:
Not specified
Approval date:
Not specified
Amendment date:
Not specified
Year:
2026
Region / City:
USA
Theme:
Amyotrophic Lateral Sclerosis (ALS) Clinical Research
Document Type:
Research Summary
Author:
NINDS ALS Outcomes Subgroup
Target Audience:
Researchers, Clinical Trials Investigators
Period of Validity:
Ongoing
Approval Date:
2026
Date of Changes:
N/A
Year:
2023
Region / Country:
Australia
Drug:
Edaravone (Radicava®)
Type of Document:
Pharmaceutical Benefits Submission
Regulatory Body:
Therapeutic Goods Administration (TGA)
Submission Purpose:
PBS Section 100 Highly Specialised Drugs Listing
Indication:
Amyotrophic lateral sclerosis (ALS)
Treatment Phase:
Initial and Continuing treatment
Prescriber Type:
Medical Practitioners, Nurse Practitioners (continuing therapy only)
Clinical Criteria:
Diagnosis by neurologist, disease duration ≤ 2 years, FVC or SVC ≥ 80% predicted, ambulatory or upper limb/swallowing ability, ALSFRS-R ≥ 2 on each item, no tracheostomy or respiratory failure
Population:
Adult patients (≥18 years)
Pricing:
Special Pricing Arrangements apply
Regulatory Dates:
Orphan designation 17 August 2021, TGA registration 15 February 2023
Comparator:
Standard of care with or without riluzole
Outcomes Measured:
ALS Functional Rating Scale – Revised (ALSFRS-R) after 6 months
Note:
Year
Topic:
Alternative Education, Enrollment
Document Type:
Enrollment Form
Institution:
Department of Education
Target Audience:
Learners, Education Administrators
Year:
2022
Location:
Redfern, NSW
Theme:
Project Management, Grants
Document Type:
Job Description
Organization:
Aboriginal Legal Service (NSW/ACT) Limited
Author:
Melanie Champion
Target Audience:
Job Applicants
Contract Duration:
3 months
Salary Range:
$136,836 - $148,198
Application Deadline:
12 May 2022
Date of Last Update:
N/A
Note:
Date
Effective:
July 11, 2005
Authorization:
LG
Page:
1 of 1
Supersedes:
April 16, 2003 Advisory, “Transferring Down a Call from ALS to BLS”
Purpose:
The purpose of this Administrative Requirement (AR) is to emphasize that the basic duties of all EMTs, pursuant to 105 CMR 170.355, are to assess and treat patients in accordance with the Statewide Treatment Protocols, to transport patients to appropriate health care facilities, and to document the assessment and care they provided.
Requirements:
Advanced Life Support (ALS) personnel who have established direct patient contact must complete an appropriate assessment in accordance with the standards of their certification and training. Based on the findings of that assessment, ALS personnel then have a duty to provide appropriate treatment in accordance with the Statewide Treatment Protocols. If an ALS intervention is initiated, or could be anticipated, for the patient, ALS personnel are required to attend the patient throughout transport, under 105 CMR 170.305(E)(3). If ALS personnel determine that an ALS intervention is not needed or anticipated, and Basic Life Support (BLS) personnel are in accord with transfer of the patient to their care for transport, the patient may be transferred to BLS for transport to an appropriate health care facility. ALS ambulance services and their medical directors must provide their ALS personnel policy guidance and instruction for performing appropriate patient assessments and for documenting the results of such assessments for all patients.
Other Policies and ARs:
See Protocol 7.7 of the Statewide Treatment Protocols, Withholding and Cessation of Resuscitation; AR 5-615, Cancellation of ALS, and Protocol 7.5 of the Statewide Treatment Protocols, Refusal of Medical Care and Transportation.
Year:
2005
Region / City:
United States
Topic:
Emergency Medical Services
Document Type:
Administrative Requirement
Issuing Body:
Office of Emergency Medical Services
Author:
Unknown
Target Audience:
ALS and BLS Personnel, EMTs, Medical Directors
Effective Period:
From July 11, 2005
Approval Date:
July 11, 2005
Amendment Date:
None
Year:
2022
Region / City:
Washington County
Topic:
Medical Equipment Inventory
Document Type:
Inventory List
Organization:
Washington County EMS
Author:
N/A
Target Audience:
EMS Personnel
Effective Date:
07/26/2022
Modification Date:
N/A
Note:
Year
Survey Data Available:
Yes / No
Year:
2023
Region:
Vallombrosa Nature Reserve, Italy
Subject:
Tree microhabitats, remote sensing metrics, and beetle biodiversity
Document type:
Scientific supplementary material
Authors:
Kraus et al., Giannetti et al.
Target audience:
Ecologists, forestry researchers, entomologists
Data collection methods:
Field survey, ALS remote sensing
Species conservation status:
CR, EN, VU, NT, LC, DD
Habitat focus:
Saproxylic and non-saproxylic beetles
Measurement parameters:
Microhabitat categories, cavity types, ALS intensity and height metrics, GLCM texture metrics
Endangered species indicators:
Critically endangered, Endangered, Vulnerable
Quantitative metrics:
Quartiles, percentiles, ratios, intensity density, entropy, GLCM statistics
Data coverage:
Tree cavities, bark, deadwood, epiphytes, nests, microsoil
Year:
2026
Region / City:
West Virginia, USA
Subject:
Health policy, ALS care
Document Type:
Legislative bill / fiscal note
Institution:
West Virginia Legislature
Author:
Delegate Young
Target Audience:
Residents with ALS, caregivers, policymakers
Period of Effect:
Upon passage
Date Introduced:
February 09, 2026
Date Referred:
Committee on Health and Human Resources
Legislative Purpose:
Establish ALS care programs, assistive technology access, multidisciplinary clinics, and ramp loan programs
Key Provisions:
Care services coordination, medical equipment and assistive technology programs, multidisciplinary ALS clinics, ramp reutilization loans
Year:
2017
Journal:
Journal of Neurology Research and Therapy
Volume:
2
Issue:
1
Pages:
34–38
Author:
Reginald F. Baugh
Affiliation:
The University of Toledo, Department of Surgery, Division of Otolaryngology
City:
Toledo, Ohio
Country:
United States
Academic Editor:
Gaetano Zaccara
Publisher License:
Creative Commons Attribution License
Keywords:
Cyanobacteria, BMAA, Amyotrophic Lateral Sclerosis, Gut microbiome
Article ID:
JNRT-16-1293
DOI:
10.14302/issn.2470-5020.jnrt-16-1293
Received:
September 18, 2016
Accepted:
October 08, 2016
Published:
September 21, 2017
Type of document:
Scientific research article
Field of study:
Neurology, Environmental Health, Microbiology
Institution:
The University of Toledo
Country of research context:
United States
Year:
2025
Region / City:
Coulee Region, La Crosse, WI, USA
Subject:
Youth service and nonprofit funding
Document Type:
Application form
Organization:
Rotary Club of La Crosse Downtown
Author:
Rotary Club of La Crosse Downtown
Target Audience:
Nonprofit organizations serving youth in the Coulee Region
Eligibility Criteria:
501c3 public charity status, experience serving youth, alignment with Rotary International mission
Application Deadline:
Not specified
Submission Address:
P.O. Box 1914, La Crosse, WI 54602-1914, [email protected]
Project Types:
New, expanded, or ongoing youth programs
Evaluation Requirements:
Description of measurable impact and plan for continued funding
Year:
2012–2019
Region:
Europe, North America, Asia, Australia, South America, Africa
Document Type:
Supplementary Table
Subject:
Genetic mutation frequency in neurodegenerative diseases
Lab Method:
Repeat-primed PCR, PCR, Fragment length analysis, Genotyping-PCR, Short tandem repeat fragment length assay
Study References:
Smit et al., 2013; Majounie et al., 2012c; Van der Zee et al., 2013; Tsai et al., 2012; Nel et al., 2019; Jang et al., 2013; Konno et al., 2013; Borghero et al., 2014; Cintra et al., 2018; Lysogorskaia et al., 2015; Masso et al., 2014; Zou et al., 2013
Population:
European, Non-European, including specific ethnic groups
Sample Size:
1–1,727 per cohort
ALS Types:
Familial ALS (fALS), Sporadic ALS (sALS)
FTD Types:
ALS/FTD, Frontotemporal dementia (FTD), Sporadic FTD (sFTD)
Geographic Origin:
Specific countries and ethnic groups as listed in the tables
Data Type:
Incidence and proportion of C9orf72 HRE carriers among disease cohorts
Year:
2025-2026
Region / City:
South Carolina
Topic:
Literary Advocacy
Document Type:
Resolution
Author:
South Carolina House of Representatives
Target Audience:
General public, literary community
Period of Action:
2025-2026
Approval Date:
January 15, 2026
Date of Changes:
N/A